Drugs / H2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04633980 | Dec 2020 → Jun 2022 | COVID-19 | University Hospital, Grenoble | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | H2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04633980 ↗ |
| Known as | molecular dihydrogen | “This study focuses on the potential use of molecular dihydrogen (H2) inhalation as an adjunctive treatment for COVID-19.” PMID 39016593 ↗ Jul 2024 |
| Action | Inhibit | “H2 therapy shows promise in inhibiting intracellular signaling pathways associated with inflammation” PMID 39016593 ↗ Jul 2024 |
| Modality | Other / unclassified | “molecular dihydrogen (H2) inhalation” PMID 39016593 ↗ Jul 2024 |
| Route | Intranasal | “Route of administration: intra-nasal” NCT04633980 ↗ |